Full Press Release Details
BiondVax's global intellectual property portfolio
ZIONA, ISRAEL, January 27, 2016. BiondVax
Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical
trials, announced today that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in
Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent.
invention covers the use of BiondVax's universal flu vaccine as a prime-boost to the current commercially available flu
vaccine. Results from BiondVax's completed clinical trials have shown significantly increased effectiveness against multiple
Babecoff, CEO of BiondVax commented, "Current
flu vaccines are strain specific and are not particularly effective against circulating wild-type' strains due to
mismatches. In fact, last year's seasonal flu vaccine was only 23% effective1. Conversely, our vaccine provides
long-lasting and higher effectiveness against multiple flu strains."
Dr. Babecoff, "Our newly approved US patent demonstrates the novel nature of our vaccine technology and strengthens
our IP portfolio for many years to come."
BiondVax Pharmaceuticals Ltd.
is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection
against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination
of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting
and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.
Science Park, 14 Einstein Street, PO Box 4143, Nes Ziona 74140, Israel
Tel: +972 8 930 2529 Fax:+972 8 930 2531 www.biondvax.com
press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such
as "expect," "believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements
involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events
and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected
by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug
development involves a lengthy and expensive process with uncertain outcome, BiondVax's ability to continue obtaining and
maintaining intellectual property protection for our Universal Flu Vaccine, risks inherent in the development and commercialization
of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization.
The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and
Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes
no obligation to update or revise any forward-looking statements.
further information, please contact:
Science Park, 14 Einstein Street, PO Box 4143, Nes Ziona 74140, Israel
Tel: +972 8 930 2529 Fax:+972 8 930 2531 www.biondvax.com